MS patients in rural areas are 17% less likely to receive DMTs than those in urban areas, a study of Alberta, Canada, ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Aranzazu Calzado, known to friends as Zazu, has lived in Houston since 1996 after moving from Spain. Diagnosed with primary ...

Biostate AI and the Accelerated Cure Project will to develop AI models to predict multiple sclerosis progression and ...

MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Balance issues with MS make it difficult for columnist Leigh Anne Nelson to navigate stairs and aisles at stadium events.

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.